You are here

The Study Of Azithromycin Switch Therapy For Treatment Of Community Acquired Pneumonia (CAP)

Last updated on March 14, 2019

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Seto-shi, Aichi-ken, Japan
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Community Acquired Pneumonia (CAP)
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
16-80 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- 16 years of age or older patients with CAP.

- Patients who were diagnosed as moderate in severity.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Known or suspected hypersensitivity or intolerance to azithromycin, other macrolides,
or ketolides.

- Hepatic dysfunction (AST, ALT, total bilirubin > 3 times institutional normal).

- Severe renal dysfunction (creatinine clearance

- Patients who have a history of severe heart diseases (4th -degree of NYHA). Patients
who have a congenital or sporadic long QT syndrome, or who are received the drugs with
reported QT prolongation.

- Severe underlying disease.

NCT00809328
Pfizer
Completed
The Study Of Azithromycin Switch Therapy For Treatment Of Community Acquired Pneumonia (CAP)

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now